SCHEMBL14770538

SCHEMBL14770538

CC(c1ccc(OCc2cc(F)ccc2F)cc1)c1nc2cc(F)c(F)cc2[nH]1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1C Q13936 1/20 0.40
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MEN1 O00255 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
ALPG P10696 1/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP1B1 Q16678 1/20 0.36
PTGES O14684 1/20 0.36
ALOX5 P09917 1/20 0.36
LTC4S Q16873 1/20 0.36
MAOB P27338 1/20 0.35
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
SLC6A4 P31645 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770531 0.93 CACNA1C (0.40) CACNA1CKDM4ELMNAHSD17B10MEN1
SCHEMBL14770539 0.90 CACNA1C (0.45) CACNA1CKDM4ELMNAHSD17B10MEN1
SCHEMBL14770536 0.89 CACNA1C (0.45) CACNA1CKDM4ELMNAHSD17B10MEN1
SCHEMBL14770530 0.89 CACNA1C (0.38) CACNA1CKDM4ELMNAHSD17B10MEN1
SCHEMBL14770527 0.89 CACNA1C (0.38) CACNA1CMEN1KMT2ACYP1A1CYP1A2
SCHEMBL14770537 0.89 CACNA1C (0.38) CACNA1CKDM4ELMNAHSD17B10MEN1
SCHEMBL14770532 0.89 AMY1A (0.38) CACNA1CMEN1HTTKMT2ACYP1A1
SCHEMBL14770528 0.88 NPC1 (0.42) CACNA1CLMNAMEN1HTTKMT2A
SCHEMBL14770526 0.88 CACNA1C (0.48) CACNA1CKDM4ELMNAHSD17B10MEN1
SCHEMBL14770529 0.86 FFAR1 (0.38) CACNA1CLMNACYP1A1CYP1A2CYP1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A CACNA1C 16/4885KDM4E 4045/4885LMNA 4407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.